placebo to match tiotropium

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 4

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03474081

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-03-29End: 2019-07-17Updated: 2021-07-15

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478696

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-18Updated: 2020-10-28

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT03478683

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2018-06-25End: 2019-03-14Updated: 2020-10-28

Related Papers

Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.

2021-04-1215 citations

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.

2020-05-2930 citations